From Wikipedia, the free encyclopedia
|Source||Humanized (from rat)|
| (what is this?)
Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract. As of September 2009[update], the drug is undergoing Phase II/III clinical trials.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|